IGC Pharma (IGC) received a Notice of Allowance from the United States Patent and Trademark Office for its patent application US 17/613,909. The patent application, IGC510, is for a proprietary method for treating individuals suffering from stammering, stuttering, or Tourette’s syndrome with THC and/or CBD.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGC:
- IGC Pharma expands CALMA Phase 2 trial with Lynn Health Science Institute site
- IGC Pharma reports Q1 EPS (2c) vs. (3c) last year
- Igc Pharma’s Risky Venture: Navigating Financial Instability Amid Bitcoin Investment Plans
- IGC Pharma highlights preclinical data on IGC-M3
- Trump Trade: Nvidia, AMD said to pay U.S. cut from China chip sales